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        SPARC (secreted protein, acidic and rich in 
cysteine, also called osteonectin and BM-40) 
belongs to the group of matricellular proteins, 
which are nonstructural proteins present in the 
extracellular matrix (ECM). Although they do 
not contribute directly to tissue integrity, they 
are potent modulators of cellular function. 
SPARC is involved in tumor progression and 
wound healing via its regulation of cell  –  ECM 
interactions and ECM production (  1, 2  ). Expres-
sion of SPARC is increased after myocardial 
infarction (MI) and is spatially and temporally 
related to the formation of a fi  brous scar (  3, 4  ). 
Although previous studies indicate a role for 
SPARC in cutaneous wound healing (  5, 6  ), evi-
dence for a specifi  c role for SPARC in granu-
lation and ECM formation in an infarcted heart 
is lacking. 
  Healing after MI requires a tightly regulated 
process of wound healing and scar formation 
that consists of three overlapping phases. The 
initial infl  ammatory phase for removal of dead 
tissue is followed rapidly by the formation of 
granulation tissue, which is rich in leukocytes, 
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  The matricellular protein SPARC (secreted protein, acidic and rich in cysteine, also known 
as osteonectin) mediates cell  –  matrix interactions during wound healing and regulates the 
production and/or assembly of the extracellular matrix (ECM). This study investigated 
whether SPARC functions in infarct healing and ECM maturation after myocardial infarc-
tion (MI). In comparison with wild-type (WT) mice, animals with a targeted inactivation of 
  SPARC   exhibited a fourfold increase in mortality that resulted from an increased incidence 
of cardiac rupture and failure after MI.   SPARC  -null infarcts had a disorganized granulation 
tissue and immature collagenous ECM. In contrast, adenoviral overexpression of   SPARC   in 
WT mice improved the collagen maturation and prevented cardiac dilatation and dysfunc-
tion after MI. In cardiac fi  broblasts in vitro, reduction of SPARC by short hairpin RNA 
attenuated transforming growth factor      (TGF)  –  mediated increase of Smad2 phosphoryla-
tion, whereas addition of recombinant SPARC increased Smad2 phosphorylation concordant 
with increased Smad2 phosphorylation in   SPARC  -treated mice. Importantly, infusion of 
TGF-     rescued cardiac rupture in   SPARC  -null mice but did not signifi  cantly alter infarct 
healing in WT mice. These fi  ndings indicate that local production of SPARC is essential for 
maintenance of the integrity of cardiac ECM after MI. The protective effects of SPARC 
emphasize the potential therapeutic applications of this protein to prevent cardiac dilata-
tion and dysfunction after MI. 
© 2009 Schellings et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the fi  rst six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons
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null mice (  Table I  ).   Four male SPARC-null mice that did 
not die from cardiac rupture displayed severe shortness of 
breath within 7 d. Two of them died prematurely (6 d after 
MI), whereas the other two were killed after echocardiogra-
phy at 7 d after MI. The fractional shortening of these two 
mice pointed toward severe systolic dysfunction (7.1   ±   3.9%), 
which was associated with signifi  cantly increased lung weight/
body weight ratios in the four male   SPARC  -null mice surviving 
new vessels, and proliferating fi  broblasts. The fi  nal, matura-
tion phase is characterized by a regression of granulation tissue 
and a progressive maturation of the collagenous ECM. Alter-
ations in this well orchestrated response to myocardial necro-
sis leads to adverse infarct healing, cardiac rupture, and cardiac 
dysfunction (  7  ). SPARC modulates ECM turnover in part 
through its eff  ect on collagen synthesis, extracellular proteases, 
and growth factors (  1  ). In addition, SPARC binds to TGF-     
receptor type II in the presence of TGF-     and thereby aff  ects 
its downstream signaling in mesangial cells (  8  ). 
  Because SPARC is increased after MI and can aff  ect 
ECM organization, we hypothesized that SPARC regulates 
infarct healing and ECM maturation after MI and might 
thereby protect against cardiac rupture and dysfunction. Our 
data reveal that loss of   SPARC   results in the formation of a 
disorganized scar and immature collagen matrix after MI. 
Adverse infarct healing in   SPARC  -null hearts evolves into 
increased cardiac rupture and dysfunction, whereas adenovi-
ral overexpression of   SPARC   protects against cardiac dilata-
tion and failure after MI. SPARC is therefore a promising 
target to obtain proper infarct healing and collagen matura-
tion and prevent cardiac rupture, dilatation, and dysfunction 
after MI. 
    RESULTS   
  SPARC expression is induced after MI 
  To assess the expression of SPARC in the cardiac healing pro-
cess, we examined SPARC protein expression in myocardial 
tissue of WT mice after MI. Immunoblotting of SPARC in 
noninfarcted remote left ventricle (LV) only revealed a mod-
erate increase of SPARC protein expression at 3 d after MI 
(  Fig. 1 A  ).   In contrast, and concordant with previous fi  ndings 
(  3, 4  ), SPARC protein levels were strongly increased in the 
infarcted LV at 7 and 14 d after MI (  Fig. 1 A  ). Immunohisto-
chemistry confi  rmed that SPARC was low to absent in 
sham-operated (  Fig. 1 B  ) and in noninfarcted remote LV 
(  Fig. 1 C  ) but abundantly present in the infarcted LV (  Fig. 1, 
C and D ). Double immunohistochemistry revealed that SPARC 
mainly colocalized with       –  smooth muscle actin  –  positive cells 
(infi  ltrating myofi  broblast;   Fig. 1, E  –  G  ) and CD45-immuno-
reactive leukocytes (  Fig. 1, H  –  J  ). Thus, SPARC protein 
showed a localized deposition contemporaneous with the 
formation of granulation tissue and progressive maturation 
of the infarct scar. 
  Increased SPARC after MI protects against cardiac rupture 
and dysfunction 
  To evaluate the function of SPARC in ECM maturation, we 
used a model of permanent coronary occlusion. The absence 
of   SPARC   was associated with a signifi  cantly increased inci-
dence of cardiac rupture after MI: 41% (13/32) of   SPARC  -
null mice (males, 8/12; females, 5/20) compared with 9% 
(3/34) of WT mice (males, 2/14; females, 1/20) died as a re-
sult of cardiac rupture (  Fig. 2, A  –  C  ).   Increased lung weight/
body weight ratios at 3 d after MI in   SPARC  -null compared 
with WT mice pointed toward cardiac dysfunction in   SPARC  -
    Figure 1.         SPARC expression is induced after MI.   (A) SPARC pro-
tein is increased after MI in mice. Representative Western blots of 
SPARC in remote and infarcted LV from WT mice at 3, 7, and 14 d after 
MI (  n   = 4 per time point; *, P   <   0.05). (B  –  D) SPARC immunofluorescent 
staining (green) is absent in sham-operated hearts (B) and remote LV 
(R-LV), gradually increases in the infarct border LV (IB-LV; C), and is 
strongly up-regulated in the infarcted LV (I-LV) 7 d after MI (C and D). 
(E  –  J) SPARC expression (E and H) colocalizes with     – smooth  muscle 
cell (SMC) actin  –  positive myofibroblasts (F and G) and CD45 immuno-
reactive leukocytes (I and J) in the infarcted LV of WT infarcted hearts 
7 d after MI. The insets in H  –  J show detailed SPARC and CD45 immuno-
reactive leukocytes. Error bars represent the mean   ±   SEM. Bars: 
(B  –  D, H, and J) 100   μ  m; (E  –  G) 50   μ  m.     JEM VOL. 206, January 19, 2009 
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between infarcted female   SPARC  -null and WT mice at 14 d 
after MI (  Fig. 2, D and E  ). However, hemodynamic stress 
induced by dobutamine increased contractility and relaxation 
in infarcted female WT mice but to a lesser extent in female 
  SPARC  -null mice (  Fig. 2, D and E  ). Systolic blood pressure 
and heart rate did not diff  er signifi  cantly after dobutamine 
infusion between infarcted female WT and   SPARC  -null 
mice (  Fig. 2, F and G  ). Although   SPARC   defi  ciency does 
cardiac rupture (14.1   ±   0.7 vs. 9.7   ±   1.3 in WT mice; 
P   <   0.05). 
  Left ventricular pressure and heart rate were similar in 
sham-operated and infarcted WT and   SPARC  -null mice at 
baseline. Systolic function, as measured by echocardiography, 
was reduced in infarcted compared with sham-operated mice 
at 3, 7, and 14 d after MI but to a similar extent in both geno-
types (  Table I  ). Baseline dP/dt  max   and dP/dt  min   did not diff  er 
    Figure 2.         Absence of   SPARC   results in cardiac rupture and dysfunction.   (A) Kaplan-Meier curve showing that targeted deletion of   SPARC   resulted 
in decreased survival of   SPARC  -null (mainly male) compared with WT mice after MI (*, P   <   0.05). Decreased survival was mainly caused by cardiac rupture. 
Two male SPARC-null mice had to be killed at 7 d after MI because of severe shortness of breath and, therefore, were not included in the survival curve. 
(B and C) Histological analysis of ruptured LV of male   SPARC  -null infarcted hearts (hematoxylin and eosin stained) revealing rupture site (B, arrows), in-
tramural hemorrhages of the infarcted ventricular wall (C, arrows), and massive infi  ltration of erythrocytes and infl  ammatory cells (C) and thrombi 
(B and C, asterisks) at 3 d after MI. (D  –  G) Decreased survival is associated with depressed cardiac contractility (D) and relaxation (E) during infusion of 
dobutamine in   SPARC  -null female (  n   = 7) in comparison with female WT (  n   = 9) mice 14 d after MI, whereas systolic blood pressure (BP; F) and heart rate 
(G) did not differ signifi  cantly (*, P   <   0.05). bpm, beats per minute. Error bars represent the mean   ±   SEM. Bars: (B) 200   μ  m; (C) 100   μ  m.     116 SPARC AND MYOCARDIAL INFARCTION   | Schellings et al. 
    SPARC  -null infarcts exhibit disorganized granulation tissue 
and defi  cient scar maturation 
  Infarct size did not signifi  cantly diff  er between WT and 
  SPARC  -null mice (  Table III  ).   Histopathological analysis of 
infarcts revealed a disorganized scar tissue with diff  use RBC 
infi  ltration in   SPARC  -null infarcts (  Fig. 3, A  –  D  ).   Adverse 
infarct healing in   SPARC  -null mice was not related to sig-
nifi  cant diff  erences in infl  ammation or vascular density, ex-
cept for the area of myofi  broblasts, which was signifi  cantly 
increased in   SPARC  -null infarcts (  Table III  ). 
  Sirius red polarization microscopy of collagen fi  bers re-
vealed a predominance of loosely assembled (yellow-green) 
collagen fi  bers in   SPARC  -null infarcts at 14 d (ratio of or-
ange-red/yellow-green birefringent collagen), which was in 
contrast to the well aligned and thick tightly packed (orange-
red) fi  bers in WT infarcts (  Fig. 3, E  –  H  ;   Table III  ). Ultra-
structural analysis confi  rmed a disorganized and immature 
collagen matrix in   SPARC  -null infarcts, as indicated by the 
decreased diameter of collagen fi  brils, which was in contrast 
to the well structured collagen matrix in WT infarcts (  Fig. 3, 
I  –  K  ). Ultrastructural and histological analysis of the cardiac 
matrix in   SPARC  -null and WT sham mice did not reveal 
signifi  cant diff  erences. 
  The absence of   SPARC   did not aff  ect collagen synthesis, 
as is shown by the lack of signifi  cant diff  erences in the fraction 
not aff  ect cardiac structure or performance of the heart under 
physiological conditions, increased levels of SPARC appear 
to play a pivotal role in the healing process by maintenance 
of the structural integrity of the heart after MI. 
  To investigate whether the absence of   SPARC   or gen-
der diff  erences resulted in compensatory changes in expres-
sion of SPARC-related factors before the onset of cardiac 
rupture, we determined transcript levels in male and female 
sham and 3-d-old infarcted hearts of   SPARC  -null and WT 
mice. SMOC1, SMOC2, and Hevin were selected because 
previous studies described their expression in the heart (  9  –  11  ), 
but little is known about the biological function of these 
proteins in the heart. Interestingly, transcript levels of 
  SMOC2   were signifi  cantly increased in WT and   SPARC  -
null female sham mice in comparison with male sham mice, 
whereas its expression decreased signifi  cantly after MI with 
no signifi  cant diff  erences between the genders (  Table II  ).   
In contrast,   SMOC1   expression signifi  cantly increased 3 d 
after MI but did not signifi  cantly diff  er between the genders 
or genotypes. Transcript levels of   Hevin   slightly decreased 
after MI, reaching signifi  cance in the infarcted female WT 
mice in comparison with the respective sham. Finally, 
  SPARC   transcript levels signifi  cantly increased at 3 d after 
MI in WT mice but did not signifi  cantly diff  er between the 
genders (  Table II  ). 
    Table I  .      Functional analysis of WT and   SPARC  -null mice after MI 
Sham MI, 3 d MI, 7 d MI, 14 d
WT,   n   = 12 
(M/F: 6/6)
null,   n   = 13 
(M/F: 4/9)
WT,   n   = 10 
(M/F: 5/5)
null,   n   = 11 
(M/F: 5/6)
WT,   n   = 7 
(M/F: 3/4)
null,   n   = 7 
(F: 7)
WT,   n   = 9 
(F: 9)
null,   n   = 9 
(F: 9)
FS (%) 26   ±   1.3 30   ±   2.2 14   ±   3.1  b 16    ±   2.6  b   18   ±   3.1  b 15    ±   7  b   12   ±   1.4  b 12    ±   1.2  b 
LVIDd (mm) 3.7   ±   0.1 3.6   ±   0.1 4.2   ±   0.2  b 4.1    ±   0.2  b 4.7    ±   0.2  b 4.9    ±   0.5  b 5.0    ±   0.3  b 5.3    ±   0.2  b 
LVIDs (mm) 2.8   ±   0.1 2.5   ±   0.1 3.6   ±   0.2  b 3.5    ±   0.2  b   3.9   ±   0.3  b 4.3    ±   0.6  b 4.4    ±   0.3  b 4.7    ±   0.3  b 
PWd (mm) 1.0   ±   0.1 0.9   ±   0.1 0.7   ±   0.1  b 0.8    ±   0.1  b   0.8   ±   0.1 0.9   ±   0.1  1.0   ±   0.1  1.0   ±   0.1
IVSd (mm) 0.9   ±   0.1 1.0   ±   0.1 0.7   ±   0.1  b  0.9   ±   0.1  a   1.0   ±   0.2 0.9   ±   0.1  0.8   ±   0.1  0.8   ±   0.1
HW/BW 5.2   ±   0.2 5.2   ±   0.2  5.6   ±   0.2  5.8   ±   0.3  7.0   ±   0.3  b   7.9   ±   0.8  b 6.4    ±   0.1  b 7.2    ±   0.3  ab 
LW/BW 6.4   ±   0.4 5.9   ±   0.2  6.4   ±   0.2 7.4   ±   0.3  ab 9.7    ±   1.3  b   10   ±   1.2  b 10    ±   1.3  b 9.8    ±   1.2  b 
M, male; F, female; FS, fractional shortening; LVIDd, left ventricular internal diameter diastole; PWd, posterior wall diastole; IVSd, intraventricular septum diastole; HW, heart 
weight; BW, body weight; and LW, lung weight.
  a  P   <   0.05 in SPARC-null versus WT infarcts.
  b  P   <   0.05 in infarcted versus sham.
    Table II.        Transcript levels of SPARC-related factor messenger RNAs (mRNAs) 
Sham 3-d MI
WT M  
  (  n   = 7)
WT F  
  (  n   = 7)
KO M  
  (  n   = 7)
KO F  
  (  n   = 7)
WT M  
  (  n   = 6)
WT F  
  (  n   = 8)
KO M  
  (  n   = 5)
KO F  
  (  n   = 10)
  SMOC1 11    ±   1.1 12   ±   1.5 13   ±   4.3 11   ±   1.4  35   ±   6.8  a 34    ±   5.3  a 26    ±   6.4  a   27   ±   5.4  a 
  SMOC2 5.0    ±   0.9  10   ±   0.5  b 7.3    ±   0.6 9.3   ±   0.3  b 3.4    ±   0.5 3.0   ±   0.5  a 4.2    ±   0.7  a 4.8    ±   0.6  ac 
  Hevin 1.0    ±   0.1 1.2   ±   0.1 1.0   ±   0.1 0.8   ±   0.1  c 0.8    ±   0.1 0.7   ±   0.1  a 0.6    ±   0.1 0.7   ±   0.1
  SPARC 3.4    ±   1.5 1.8   ±   0.1 ND ND 14   ±   1.6  a 16    ±   1.8  a ND ND
M, male; F, female; ND, not detectable. Numbers are in arbitrary units.
  a  P   <   0.05 in MI group versus respective sham.
  b  P   <   0.05 between males and females of the same genotype.
  c  P   <   0.05 between WT and SPARC-null mice of the same gender.JEM VOL. 206, January 19, 2009 
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altered signaling of TGF-    , which is a known profi  brotic cyto-
kine (  12  ). The levels of phosphorylated and total Smad2 were 
signifi  cantly higher in the infarcts of AdSPARC-treated WT 
mice (  Fig. 5 A  ).   These results were concordant with experi-
ments in vitro, which showed that addition of recombinant 
SPARC increased Smad2 phosphorylation at baseline as well 
as after stimulation with TGF-    1 (  Fig. 5 B  ). Inhibition of 
SPARC by short hairpin RNA (shRNA) resulted in an 80% 
decrease in levels of SPARC protein (  Fig. 5 C  ). Although 
treatment with 1 ng/ml TGF-     resulted in a signifi  cant in-
crease in the ratio of phosphorylated Smad2 (p-Smad2) to to-
tal Smad2 protein in control fi  broblasts (100   ±   4% in control 
compared with 272   ±   30% in TGF-      –  treated fi  broblasts;   n   = 5; 
P   <   0.05), the decrease in SPARC signifi  cantly blunted the 
ratio of p-Smad2/Smad2 at baseline (66   ±   8%;   n   = 6; P   <   
0.05 compared with WT fi  broblasts) and after treatment with 
TGF-     (234   ±   14%;   n   = 5; P   <   0.05 compared with TGF-
      –  treated WT fi  broblasts;   Fig. 5 C  ). We did not fi  nd signifi  -
cant diff  erences in Smad2 phosphorylation between WT and 
  SPARC  -null infarcts, a result which might refl  ect the in-
creased presence of myofi  broblasts in the   SPARC  -null infarcts. 
Together, these data confi  rm a role for SPARC in the regu-
lation of TGF-     signaling. 
  Infusion of TGF-     protects against cardiac rupture 
in   SPARC  -null mice 
  TGF-     is strongly implicated in infarct healing and remodel-
ing after MI. To investigate whether aberrant TGF-     signaling 
in the absence of   SPARC   is involved in the adverse infarct 
healing and increased cardiac rupture after MI observed in 
  SPARC  -null animals,   SPARC  -null and WT mice were treated 
with TGF-    . 
  Administration of TGF-     signifi  cantly improved the sur-
vival of   SPARC  -null animals by its diminution of cardiac 
rupture (1 out of 7 in TGF-      –  treated compared with 8 out of 
12 in saline-treated   SPARC  -null mice;   Fig. 5 D  ). Histological 
Sirius red  –  stained collagen (  Fig. 3, E and G  ;   Table III  ) or 
transcript levels of   collagen type I   and   type III   (Table S1, available 
at http://www.jem.org/cgi/content/full/jem.20081244/DC1) 
in   SPARC  -null compared with WT infarcts. Thus, in-
creased cardiac rupture and dysfunction in   SPARC  -null mice 
are related, at least in part, to defi  cient maturation of the scar 
after MI. 
  Adenoviral overexpression of   SPARC   protects against 
cardiac dilatation and dysfunction after acute MI 
  To investigate whether overexpression of   SPARC   could pre-
vent cardiac dysfunction after MI, we enhanced   SPARC   ex-
pression in WT mice by injection of a replication-defi  cient 
adenovirus harboring mouse   SPARC   (AdSPARC) 2 d before 
MI. Subsequently, there was a 2.8-fold increase in expression 
of SPARC in plasma and a 2.6-fold increase of SPARC ex-
pression in the infarct area at 14 d after MI in comparison to 
control AdR5-injected mice (  Fig. 4, A and B  ).   The increased 
levels of SPARC prevented cardiac dilatation and dysfunc-
tion after MI (  Table IV  ) without alteration of infarct size 
(  Table V  ).   SPARC signifi  cantly increased collagen deposition 
and birefringence in the infarct zone (  Fig. 4, C-F  ;   Table V  ) 
but did not aff  ect the amount of CD45-positive leukocytes, 
      –  smooth muscle actin  –  positive myofi  broblasts, and coronary 
vessels in comparison to control AdR5-treated mice (  Table V  ). 
These fi  ndings were corroborated by the increased transcript 
levels of ECM proteins in the infarcts of mice treated with 
AdSPARC (Table S2, available at http://www.jem.org/cgi/
content/full/jem.20081244/DC1). Thus, overexpression of 
  SPARC   protects against adverse collagen remodeling, which 
is associated with reduced ventricular dilatation and failure 
after MI. 
  SPARC modulates TGF-     signaling 
  We asked whether the increased collagen deposition found in 
the infarcts of SPARC-overexpressing mice was associated with 
    Table III.        Histological analysis of the infarcted area 
WT 7d  
  (  n   = 8)
  SPARC  -null, 7d  
  (  n   = 7)
WT + TGF-    , 7d  
  (  n   = 6)
  SPARC  -null + TGF-    , 
7d (  n   = 6)
WT, 14 d  
  (  n   = 10)
  SPARC  -null, 14 d 
  (  n   = 11)
Infarct size (%) 43   ±   3.6 46   ±   4.1 38   ±   3 36   ±   4 42   ±   2.6 43   ±   2.7
Residual necrotic area (%)  9.6   ±   1.8 9.6   ±   2.2 14.3   ±   6.9  3.9   ±   1.7  2.7   ±   0.7 1.0   ±   0.3  a 
Infarct thickness (  μ  m)  380   ±   61 290   ±   22 430   ±   40 560   ±   72  b   390   ±   27  380   ±   27
Leukocyte infi  ltration  
  (cells/mm  2  )
 870   ±   180  820   ±   140 720   ±   180 870   ±   80  660   ±   130  270   ±   68  a 
Coronary growth  
  (vessels/mm  2  )
 42   ±   4  45   ±   5 59   ±   5  b   59   ±   3  b   54   ±   10  43   ±   5
Capillary growth (vessels/mm  2  )  89   ±   14  119   ±   18 135   ±   31  143   ±   23  87   ±   16  116   ±   13
Myofi  broblast (% area)  2.1   ±   0.4  3.8   ±   0.8  a 1.7    ±   0.1  1.1   ±   0.2  b   0.8   ±   0.4  1.6   ±   0.2
Collagen deposition (%)  26   ±   2.5  20   ±   3.6  28   ±   2 30   ±   2  b   36   ±   2.4  37   ±   2.0
Ratio O-R thick/Y-G thin collagen 
fi  bers
 11   ±   2.3  2.5   ±   0.5  a 20    ±   2.9  b 4.5    ±   1.2  b   17   ±   1.8  8.1   ±   1.8  a 
O-R, orange-red; Y-G, yellow-green.
  a  P   <   0.05 in SPARC-null versus WT infarcts at corresponding time after MI.
  b  P   <   0.05 in TGF-      –  treated infarcts versus untreated infarcts at the corresponding time after MI.118 SPARC AND MYOCARDIAL INFARCTION   | Schellings et al. 
    Figure 3.         Adverse wound healing in   SPARC  -null mice.   (A – D)  Hema-
toxylin and eosin staining revealed a disorganized granulation tissue with 
increased RBC infi  ltration in male   SPARC  -null (C and D) versus WT 
(A and B) 7-d-old infarcts. (E  –  K) Abnormal collagen formation in   SPARC -
null infarcts. (E  –  H) Sirius red staining did not indicate substantial differ-
ences in the amount of collagen deposition between WT (E) and 
  SPARC  -null (G) infarcts at 14 d after MI. Sirius red polarization micros-
copy revealed well aligned and tightly packed (orange-red) collagen fi  bers 
in WT (F) but less mature fi  bers (yellow-green) in   SPARC  -null infarcts (H). 
(I  –  K) Ultrastructural analysis confi  rmed a disorganized matrix in   SPARC -
null (J) in comparison with WT (I) infarcts, which was associated with 
the deposition of smaller collagen fi  brils in the infarct zone of   SPARC -
null mice (K;   n   = 3). Bars: (A, C, E, and G) 200   μ  m; (B and D) 50   μ  m; 
(I and J) 5   μ  m; (K) 500 nm.     
 
    Figure 4.           SPARC   overexpression increases collagen deposition and 
quality after MI.   (A and B) Representative Western blots showing a 
2.8-fold increase of SPARC in plasma (A) and a 2.6-fold increase of SPARC 
in the infarct area (B) of AdSPARC-treated WT mice in comparison 
with AdR5-treated WT mice at 14 d after MI (  n   = 4; *, P   <   0.05). (C  –  F) Sirius 
red staining and polarization microscopy revealed increased collagen 
deposition in AdSPARC-treated (D) in comparison with AdR5-treated WT 
infarcts (C) and more well aligned and tightly packed (orange-red) collagen 
fi  bers in AdSPARC-treated (F) in comparison with AdR5-treated WT 
infarcts (E). Error bars represent the mean   ±   SEM. Bars: (C and D) 2 mm; 
(E and F) 200   μ  m.     JEM VOL. 206, January 19, 2009 
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rupture in   SPARC  -null infarcted mice, a result which under-
scores our data in vitro and in vivo showing that exogenous 
SPARC regulates TGF-     signaling. 
  Expression of SPARC increases progressively after MI 
and is seen primarily in infl  ammatory cells and fi  broblasts (  1, 4  ), 
data which indicates a role for SPARC during healing of 
the infarct scar. The increased cardiac rupture and dysfunc-
tion that we observed appeared to coincide with the disorga-
nized and fragmented granulation tissue as well as abnormal 
collagen maturation. Cardiac rupture mainly occurred in 
male mice. Hormonal status, higher blood pressure, and in-
creased physical activity during the night may predispose to 
the increased cardiac rupture, dysfunction, and mortality in 
male compared with female mice after MI (  13  –  16  ). To inves-
tigate whether diff  erences in expression of SPARC or SPARC-
related factors may infl  uence the phenotype seen after MI, 
we determined transcript levels of   SPARC   and the SPARC-
related factors   SMOC1  ,   SMOC2  , and   Hevin   in males and 
females of both genotypes. Because these SPARC-related 
factors are expressed in the heart (  9  –  11  ) and Hevin is in-
volved in collagen assembly (  17  ), these proteins may be im-
plicated in infarct remodeling. Lack of   SPARC   did not result 
in compensatory changes of SPARC-related factors. However, 
sham WT and   SPARC  -null female mice displayed increased 
analysis revealed increased deposition of collagen in TGF-      –
  treated compared with saline-treated   SPARC  -null hearts 
(  Fig. 5, E  –  L  ;   Table III  ), but no signifi  cant diff  erences in infl  am-
mation or blood vessel formation were observed (  Table III  ). 
Improved collagen maturation by infusion of TGF-     into 
  SPARC  -null infarcted mice was demonstrated by the signifi  -
cantly increased numbers of thick orange-red collagen fi  bers (ra-
tio of orange-red/yellow-green birefringent collagen, 4.5   ±   1.2 
in TGF-      –  treated compared with 2.2   ±   0.4 in saline-treated 
  SPARC  -null infarcted mice;   n   = 7; P   <   0.05;   Fig. 5, E  –  L  ; 
  Table III  ). Administration of TGF-     did not signifi  cantly af-
fect wound healing or collagen formation in WT animals 
(  Fig. 5, E  –  L  ;   Table III  ). 
    DISCUSSION   
  This study indicates a crucial role for SPARC in infarct heal-
ing and collagen formation after MI. The absence of   SPARC   
was associated with adverse healing and defi  cient maturation 
of collagen with increased cardiac rupture and dysfunction af-
ter MI. Importantly, adenoviral-mediated overexpression of 
  SPARC   (AdSPARC) in WT mice, resulting in increased 
plasma and cardiac levels of SPARC, improved collagen mat-
uration and prevented cardiac dysfunction and dilatation after 
MI. Moreover, treatment with TGF-     prevented cardiac 
    Table IV.        Functional analysis of WT mice treated with AdR5 or AdSPARC virus 
Sham MI, 14 d
AdR5,   n   = 4 AdSPARC,   n   = 4 AdR5,   n   = 9 AdSPARC,   n   = 9
FS (%) 22   ±   2.5 30   ±   2.0  a 10    ±   1.7  a 24    ±   3.4  b 
LVIDd (mm) 3.9   ±   0.1 4.1   ±   0.1 5.8   ±   0.2  a 5.0    ±   0.2  ab 
LVIDs (mm) 3.0   ±   0.1 2.9   ±   0.1 5.2   ±   0.2  a 3.8    ±   0.3  ab 
PWd (mm) 0.7   ±   0.1 0.7   ±   0.1 0.7   ±   0.1 0.8   ±   0.1  b 
IVSd (mm) 0.7   ±   0.1 0.7   ±   0.1 0.6   ±   0.1 0.7   ±   0.1  b 
HW/BW 3.9   ±   0.1 4.3   ±   0.2 5.1   ±   0.2  a 4.8    ±   0.1  a 
LW/BW 5.7   ±   0.1 5.5   ±   0.1 7.0   ±   0.5  a 5.3    ±   0.1  b 
FS, fractional shortening; LVIDd, left ventricular internal diameter diastole; LVIDs, left ventricular internal diameter systole; PWd, posterior wall diastole IVSd, intraventricular 
septum diastole; HW, heart weight; BW, body weight; and LW, lung weight.
  a  P   <   0.05 in infarcted (MI) versus sham-operated mice or AdR5 versus AdSPARC sham-operated mice.
  b  P   <   0.05 in AdvSPARC infarcts versus AdR5 infarcts.
    Table V.        Histological analysis of the infarcted area of AdR5- and AdSPARC-treated mice 
AdR5 MI, 14 d (  n   = 9) AdSPARC MI, 14 d (  n   = 9)
Infarct size (%) 35   ±   3.9 38   ±   1.4
Residual necrotic area (%) 1.5   ±   2.3 2.1   ±   1.5
Infarct thickness (  μ  m) 450   ±   16 520   ±   28
Leukocyte infi  ltration (cells/mm  2  )5 7 0    ±   91  560   ±   91
Coronary growth (vessels/mm  2  ) 32   ±   4  35   ±   3
Capillary growth (vessels/mm  2  ) 106   ±   11  113   ±   9
Myofi  broblast (% area) 1.0   ±   0.2 1.6   ±   0.2
Collagen deposition (%) 28   ±   2.3  40   ±   2.5  a 
Ratio O-R thick/Y-G thin collagen fi  bers 18   ±   3.7 60   ±   11  a 
O-R, orange-red; Y-G, yellow-green.
  a  P   <   0.05 in AdvSPARC infarcts versus AdR5 infarcts.120 SPARC AND MYOCARDIAL INFARCTION   | Schellings et al. 
    Figure 5.         SPARC and TGF-     cooperate during infarct healing.   (A) Representative Western blot showing increased phosphorylated and total Smad2 
levels in the infarcts of AdSPARC-treated mice (  n   = 9; *, P   <   0.05). (B) Representative Western blot showing that addition of recombinant mouse SPARC 
activated Smad2 signaling and augmented the Smad2-activating potential of TGF-     ( n   = 6; *, P   <   0.05). (C) The top blot is a representative Western blot 
indicating that shRNA against SPARC resulted in an 80% decrease in levels of SPARC protein. The blots are representative Western blots showing that 
Smad2 phosphorylation in shRNA-treated cardiac fi  broblasts was signifi  cantly decreased at baseline levels (left) and after 15 min of stimulation by 1 ng/ml 
TGF-     (right;   n   = 5 per group; *, P   <   0.05). (D) Survival curve showing that infusion of TGF-     protected against cardiac rupture after MI in male   SPARC -
null mice (1 out of 7 mice) in comparison with saline-treated male   SPARC  -null mice (8 out of 12 mice; *, P   <   0.05). (E, F, I, and J) Hematoxylin and eosin 
staining revealed striking differences between TGF-    – treated  WT  and   SPARC  -null mice 7 d after MI. In WT mice, infusion of TGF-     did not signifi  cantly 
affect wound healing, whereas in   SPARC  -null animals it stimulated ECM production in the infarct zone. (G, H, K, and L) Sirius Red staining and Sirius Red 
polarization microscopy revealed no apparent differences in collagen deposition between TGF-   1 – treated   SPARC  -null and WT mice, whereas the differ-
ence in well aligned and tightly packed (orange-red) collagen fi  bers in WT infarcts (H), but less mature fi  bers (yellow-green) in   SPARC  -null infarcts (L), was 
preserved. Error bars represent the mean   ±   SEM. Bars: (E, G  –  I, K, and L) 200   μ  m; (F and J) 50   μ  m.     JEM VOL. 206, January 19, 2009 
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transcript levels of   SMOC2   in comparison with male sham 
mice. In contrast,   SMOC2   transcript levels did not diff  er sig-
nifi  cantly between the genders at 3 d after MI, indicating that 
SMOC2 may not protect female mice after MI.   SMOC1   
transcript levels were strongly increased at 3 d after MI, sug-
gesting that SMOC1 may be involved in regulation of the 
infl  ammatory response. Lack of clear diff  erences in the ex-
pression pattern of   Hevin   at 3 d after MI precludes a signifi  -
cant role for this protein in cardiac rupture or early wound 
healing after MI. However, further investigation to delineate 
the specifi  c roles of SPARC-related proteins in the patho-
genesis of MI is mandatory. 
  We found that the total amount of collagen did not diff  er 
between   SPARC  -null and WT infarcts, but Sirius red polar-
ization and electron microscopy revealed a disorganized and 
immature collagen matrix in the absence of SPARC. Impor-
tantly, infarcts from AdSPARC-treated WT mice displayed 
increased collagen deposition and improved maturation in 
comparison with infarcts of mice treated with control virus, 
data which clearly emphasizes the importance of SPARC for 
appropriate infarct healing. 
  SPARC likely regulates infarct healing and collagen mat-
uration by several diff  erent mechanisms. First, SPARC di-
rectly interacts with collagen type I fi  bers (  18, 19  ) and thereby 
aff  ects their assembly. Variations in the structure of SPARC 
alter its affi   nity for collagen type I, and the absence of SPARC 
results in the formation of immature collagen fi  bers during 
wound healing in the skin (  6  ) and in response to a foreign 
body (  20  ). Moreover,   SPARC  -null fi  broblasts lack the capac-
ity to create a mature collagen matrix as a result of defects in 
procollagen processing (  19  ). A second mechanism by which 
SPARC can regulate collagen matrix maturation is the capac-
ity of SPARC to regulate fi  bronectin matrix assembly (  21  ). In 
vitro, collagen fi  bril formation is dependent on the assembly 
of fi  bronectin into fi  brils (  22  ). Previous studies revealed that 
lack of   SPARC   results in impaired fi  bronectin  unfolding, 
which is regulated via       5        1   integrin and integrin-linked ki-
nase, that could lead to the defective collagen maturation. 
  In this paper, we provide data that SPARC-mediated 
TGF-    1 signaling is important in regulating infarct healing in 
the heart. TGF-    1 is a cytokine involved in wound healing 
and collagen production, which produces multiple, and often 
opposing, cellular responses throughout the diff  erent phases 
of wound healing after MI (  12  ). Two independent studies 
demonstrated that early inhibition of TGF-     signaling in-
creased mortality and exacerbated LV dilatation and contrac-
tile dysfunction after MI, whereas blocking TGF-     signaling 
during a later phase prevented adverse LV remodeling (  23, 24  ). 
We have now shown that SPARC regulates TGF-     signal-
ing in cardiac fi  broblasts and demonstrate that the increased 
TGF-     signaling in the infarct is benefi  cial for strengthening 
of the infarct scar. These fi  ndings are concordant with previous 
observations of SPARC-mediated TGF-     signaling in epi-
thelial (  25  ) and mesangial (  8  ) cells. Our fi  nding that treatment 
with TGF-     prevented infarct rupture and rescued collagen 
maturation in   SPARC  -null mice, but did not signifi  cantly af-
fect infarct healing in WT animals, provides strong evidence 
in vivo for an important role for SPARC-mediated TGF-     
signaling in infarct healing and collagen maturation after MI. 
  The importance of matricellular proteins and proteogly-
cans in cardiac wound healing and remodeling has previously 
been noted (  26  ). These macromolecules, which are minimally 
expressed in the normal uninjured heart, are highly up-regu-
lated in the injured heart. Recent publications have described 
roles for thrombospondin-1 (  27  ), osteopontin (  28  ), tenascin-C 
(  29  ), and syndecan-1 (  30  ) in wound healing of the infarcted 
heart. Thrombospondin-1 and syndecan-1, which are expressed 
early after MI, serve as a   “  barrier  ”   limiting the infl  ux of in-
fl  ammatory cells and thereby regulate proper infarct healing 
and prevent infarct expansion and cardiac dilatation. In con-
trast, osteopontin (  3, 28  ), tenascin-C (  29  ), and SPARC (  3, 4  ) 
are expressed principally during the formation of granulation 
tissue and fi  brous scar and are implicated in the assembly and 
maturation of collagen fi  bers. 
  In conclusion, this is the fi  rst study to reveal that expres-
sion of SPARC after MI is essential for proper infarct healing 
and function after MI. SPARC should be considered as a 
novel therapeutic agent to improve cardiac remodeling and 
function after MI. 
  MATERIALS AND METHODS 
  Mouse model of MI.     All described study protocols were approved by the 
Animal Care and Use Committee of the University of Maastricht and Leu-
ven. Experiments were performed according to the offi   cial rules formulated 
in the Dutch and Belgian law on care and use of experimental animals. 130 
10  –  18-wk-old male and female   SPARC  -null mice (backcrossed 10 times) 
and WT animals on a C57Bl6/J background were used in this study, and all 
experiments were performed using age-matched mice. Experimental MI and 
sham operation were performed as previously described (  16  ). Hearts were 
perfused with PBS, removed, and prepared for molecular, histological, and 
ultrastructural analysis. 
  Histology and electron microscopy.     Cardiac tissue was processed and 
histochemical and immunohistochemical analyses were performed as previ-
ously described (  16, 30  ). Percentage of infarct size was expressed as the frac-
tional circumference of the infarcted versus infarcted plus noninfarcted left 
ventricular wall and septum, which was assessed by measuring the midline 
circumference of three sections of the LV on hemalum eosin  –  stained sec-
tions. Infarct thickness (in micrometers) was measured as the mean of 20 
measurements across the infarcted LV wall. Residual necrotic area was deter-
mined as the percentage of the total infarcted area. Myofi  broblast infi  ltration 
was studied as the fractional areas of the infarct stained for     -SMC actin 
(DAKO), excluding coronary vessels. The number of CD-45  –  staining cells 
(BD), CD-31  –  staining capillaries (BD), and     -SMC actin  –  positive coronary 
vessels (Sigma-Aldrich) in the infarct zone was measured per mm  2  . For co-
localization studies, sections were subsequently incubated with Biotin-labeled 
secondary antibodies followed by amplifi  cation with the signal amplifi  cation 
system (streptavidin-HRP-C-fl   uorescein/Cy3; PerkinElmer) for SPARC 
(R  &  D Systems), CD45, and     -SMC. Nuclei were stained with DAPI 
(Invitrogen). 
  To assess the quality of the newly formed collagen matrix, Sirius Red 
staining was performed as previously described (  30, 31  ). The quality of the 
newly deposited collagen matrix was studied with Sirius Red polarization 
microscopy, quantifying the ratio of the thick closely packed mature colla-
gen fi  bers as orange-red birefringent to the loosely packed less cross-linked 
and immature collagen fi  bers as yellow-green birefringent (orange-red/
yellow-green ratio). 122 SPARC AND MYOCARDIAL INFARCTION   | Schellings et al. 
  TGF-     infusion in SPARC-null and WT mice.     To investigate whether 
exogenous administration of TGF-     rescued increased cardiac rupture after 
MI, we treated SPARC-null and WT mice with 250 ng/d TGF-     versus 
saline for 7 d using osmotic minipumps. 
  Statistical analysis.     Data were expressed as the mean   ±   SEM. No repeated 
measures were performed. Echocardiographic measurements and histologi-
cal and molecular analysis in sham-operated and infarcted groups at 3, 7, and 
14 d were performed in independent groups. Normal distribution of all con-
tinuous variables was tested according to the method of Kolmogorov and 
Smirnov. An unpaired Student  ’  s   t   test was used in most of the comparisons 
when groups passed the normality test. 
  A Mann-Whitney test was used when the SD of two groups signifi  -
cantly diff  ered. A two-way ANOVA was used for comparison of the dobu-
tamine curves. Survival curves after MI were obtained by the Kaplan-Meier 
method and compared by the log-rank test. A two-sided p-value of   <  0.05 
was considered statistically signifi  cant. 
  Online supplemental material.     Table S1 shows the transcript levels of 
ECM mRNAs in sham and infarcted WT and   SPARC  -null mice. Table S2 
shows the transcript levels of ECM mRNAs in sham and infarcted AdR5- 
and AdSPARC-treated WT mice, confi  rming increased ECM deposition 
in AdSPARC-treated infarcts. Table S3 shows the sequences used for the 
creation of shRNA against SPARC. Table S4 shows the primers used with 
real-time PCR. Online supplemental material is available at http://www
.jem.org/cgi/content/full/jem.20081244/DC1. 
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